|
hepatocellular carcinoma |
24 |
|
transarterial chemoembolization |
13 |
|
cancer staging |
11 |
|
cancer survival |
11 |
|
controlled study |
11 |
|
liver transplantation |
11 |
|
cirrhosis |
10 |
|
liver transplant |
10 |
|
molecular biology |
10 |
|
molecular pathology |
10 |
|
signaling |
10 |
|
adult |
9 |
|
medical sciences |
9 |
|
cardiac function |
8 |
|
gastroenterology medical sciences |
8 |
|
gene mutation |
8 |
|
high-intensity focused ultrasound |
8 |
|
next-generation sequencing |
8 |
|
outcomes |
8 |
|
rsk2 |
8 |
|
stereotactic body radiation therapy |
8 |
|
surgery |
8 |
|
unresectable |
8 |
|
waiting list |
8 |
|
abdominal abscess |
7 |
|
abdominal bleeding |
7 |
|
de novo hbv |
7 |
|
de novo hepatocellular carcinoma |
7 |
|
entecavir |
7 |
|
extended criteria organ |
7 |
|
living donor liver transplantation |
7 |
|
long-term survival |
7 |
|
antiviral therapy |
6 |
|
biliary complications |
6 |
|
cancer invasion |
6 |
|
cancer stem cells |
6 |
|
cdk1 inhibitor |
6 |
|
cholangiograms |
6 |
|
ductal anomaly |
6 |
|
endocrinology |
6 |
|
hcc |
6 |
|
hepatectomy |
6 |
|
hepatocellullar carconoma |
6 |
|
hepatocholangiocarcinoma |
6 |
|
intrahepatic cholangiocarcinoma |
6 |
|
jnk |
6 |
|
nomogram |
6 |
|
pdx models |
6 |
|
post-transplant recurrence |
6 |
|
prediction |
6 |
|
predictive model |
6 |
|
recurrence |
6 |
|
resection |
6 |
|
right liver donation |
6 |
|
ro3306 |
6 |
|
sorafenib |
6 |
|
stc1 |
6 |
|
adjuvant chemotherapy |
5 |
|
alagille syndrome |
5 |
|
animal experiment |
5 |
|
animal model |
5 |
|
anterior approach |
5 |
|
apoptosis |
5 |
|
augmented reality |
5 |
|
bile duct atresia |
5 |
|
bile duct obstruction |
5 |
|
bile duct reconstruction |
5 |
|
bile leakage |
5 |
|
cell proliferation |
5 |
|
colorectal liver metastasis |
5 |
|
complication |
5 |
|
deceased-donor liver re-transplantation |
5 |
|
graft failure |
5 |
|
hepatic artery thrombosis |
5 |
|
hepatic malignancy |
5 |
|
hepatitis |
5 |
|
hepatopancreatoduodenectomy |
5 |
|
laparoscopic hepatectomy |
5 |
|
liver resection |
5 |
|
living-donor liver re-transplantation |
5 |
|
malignancy |
5 |
|
meta-analysis |
5 |
|
oncological outcomes |
5 |
|
pancreaticojejunostomy |
5 |
|
pancreatoduodenectomy |
5 |
|
post-hepatectomy |
5 |
|
post-operative complication |
5 |
|
predicting scoring system |
5 |
|
acute rejection |
4 |
|
alpha-fetoprotein |
4 |
|
alpps |
4 |
|
antibody-mediated rejection |
4 |
|
associating liver partition and portal vein ligation for staged hepatectomy |
4 |
|
immunosuppression |
4 |
|
kidney transplantation |
4 |
|
orthotopic liver transplantation |
4 |
|
pneumocystis jirovecii |
4 |
|
pneumocystis pneumonia |
4 |
|
post-liver transplant |
4 |
|
primary biliary cirrhosis |
4 |
|
right lobe |
4 |
|
survival |
4 |
|
transplants |
4 |
|
allograft |
3 |
|
cholestasis |
3 |
|
end-stage liver disease |
3 |
|
erectile dysfunction |
3 |
|
heterogeneity |
3 |
|
hypogonadism |
3 |
|
multifocal hcc |
3 |
|
sexual dysfunction |
3 |
|
stemness |
3 |
|
anamnesis |
2 |
|
antineoplastic agents - therapeutic use |
2 |
|
axillary dissection |
2 |
|
bile duct |
2 |
|
blood clotting |
2 |
|
breast cancer |
2 |
|
breast neoplasms - drug therapy - pathology - surgery |
2 |
|
case report |
2 |
|
chronic hepatitis b |
2 |
|
end-stage liver diseases |
2 |
|
endoscopic retrograde cholangiopancreatography |
2 |
|
estimated standard liver volume |
2 |
|
false-negative rate |
2 |
|
hilar plate |
2 |
|
liver failure |
2 |
|
liver transection |
2 |
|
living donors |
2 |
|
lymphatic mapping |
2 |
|
propofol |
2 |
|
reoperation - statistics and numerical data |
2 |
|
right lobe living donor liver transplantation |
2 |
|
sentinel lymph node biopsy |
2 |
|
small for size syndrome |
2 |
|
trisectionectomy |
2 |
|
colorectal cancer |
1 |
|
hepatic resection |
1 |
|
liver metastases |
1 |
|
neoadjuvant therapy |
1 |
